With Phase III top-line data for CD20-targeting monoclonal antibody ublituximab showing a marked improvement in relapse rates in relapsing multiple sclerosis (RMS), TG Therapeutics, Inc.’s drug may be able to compete with other therapies on a shorter infusion time and pricing.
The company said it is planning to file for US Food and Drug Administration approval of ublituximab in the middle...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
